rPA 102

Drug Profile

rPA 102

Alternative Names: Anthrax vaccine recombinant - Emergent Biosolutions; PreviThrax; Recombinant protective antigen anthrax vaccine, purified; rPA anthrax vaccine - Emergent BioSolutions

Latest Information Update: 22 Jul 2015

Price : $50

At a glance

  • Originator United States Army Medical Research Institute of Infectious Diseases
  • Developer Emergent BioSolutions
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Anthrax
  • New Molecular Entity No

Highest Development Phases

  • Phase II Anthrax

Most Recent Events

  • 22 Jul 2015 Phase-II development is ongoing in the US
  • 04 Oct 2012 The Biomedical Advanced Research Development Authority exercises contract option to further advance the development of rPA anthrax vaccine
  • 18 Sep 2010 Emergent BioSolutions signs contract with the Biomedical Advanced Research and Development Authority for the development of a rPA anthrax vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top